Physician profile
Michael Ulm
NPI 1184917544
$6,928.94
in general payments reported to CMS, 2019-2025
48 companies · $875 in 2025
The $875 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $789 · 2020: $352 · 2021: $368 · 2022: $422 · 2023: $784 · 2024: $3,338 · 2025: $875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,760 · Consulting Fee: $2,160 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,759.58 |
| Consulting Fee | $2,160.00 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $2,178.75 | 2024-2025 | |
| Glaxosmithkline, LLC. | $996.04 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Eisai INC. | $547.78 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $369.09 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Tesaro, INC. | $324.65 | 2019 | |
| Intuitive Surgical, INC. | $248.89 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $202.68 | 2019-2024 | Enhertu, Lynparza |
| Seagen INC. | $201.26 | 2022-2023 | Tivdak |
| Daiichi Sankyo INC. | $159.62 | 2022-2025 | Enhertu, Injectafer |
| Clovis Oncology, INC. | $143.49 | 2019-2020 | |
| Ethicon US, LLC | $142.89 | 2019 | |
| Immunogen, INC. | $138.88 | 2023-2024 | Elahere, Elahere |
| Davol INC. | $135.40 | 2025 | Phasix Mesh |
| Astellas Pharma US INC | $121.26 | 2024 | |
| Myriad Genetic Laboratories, INC. | $104.47 | 2025 | Myrisk |
Show all 47 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ulm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.